Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717741 | 0.76 | KDM4E (0.36) | KDM4ETHRBLMNAALDH1A1TP53 | |
| SCHEMBL14646450 | 0.74 | KDM4E (0.37) | KDM4ETHRBLMNAALDH1A1TP53 | |
| SCHEMBL715109 | 0.71 | NPC1 (0.41) | KDM4ETHRBLMNAALDH1A1TP53 | |
| SCHEMBL718586 | 0.71 | NPC1 (0.41) | KDM4ETHRBLMNAALDH1A1TP53 | |
| SCHEMBL716870 | 0.67 | TRPM8 (0.43) | KDM4EALDH1A1POLB | |
| SCHEMBL718666 | 0.67 | TRPM8 (0.50) | KDM4ELMNAMAPTKMT2AHPGD | |
| SCHEMBL10238251 | 0.67 | NPC1 (0.42) | KDM4ETHRBLMNATP53KMT2A | |
| SCHEMBL13029609 | 0.65 | NPC1 (0.48) | KDM4ELMNAALDH1A1TP53MAPT | |
| SCHEMBL30059934 | 0.65 | NPC1 (0.48) | KDM4ELMNAALDH1A1TP53MAPT | |
| SCHEMBL14365271 | 0.63 | HPGD (0.40) | KDM4ETHRBALDH1A1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | disclosed |
| US-7897781-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897781-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| EP-2029614-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007134107-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134107-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | KDM4E 2229/4885THRB 947/4885LMNA 1848/4885 |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | KDM4E 2229/4885THRB 947/4885LMNA 1848/4885 |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | KDM4E 2229/4885THRB 947/4885LMNA 1848/4885 |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | KDM4E 2229/4885THRB 947/4885LMNA 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.